LPTX

Leap Therapeutics Inc

Add to Watchlist

Advanced Chart

0.326

-0.003(-0.912%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.3296

Open

0.310

VWAP

0.32

Vol

567.26K

Mkt Cap

13.51M

Low

0.310

Amount

182.73K

EV/EBITDA(TTM)

Total Shares

38.26M

-19.08M

EV/OCF(TTM)

P/S(TTM)

Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.

1 Analyst Rating

819.96% Upside

Wall Street analysts forecast LPTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LPTX is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

819.96% Upside

Current: 0.326

Low

3.00

Averages

3.00

High

3.00

819.96% Upside

Current: 0.326

Low

3.00

Averages

3.00

High

3.00

HC Wainwright & Co.

Swayampakula Ramakanth

Hold

Reiterates

n/a

2025-03-27

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

n/a

2025-03-27

Reiterates

Hold

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Hold

Downgrades

n/a

2025-01-29

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

n/a

2025-01-29

Downgrades

Strong Buy

Hold

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$5.5

2025-01-16

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$5.5

2025-01-16

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$5.5

2024-11-15

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$5.5

2024-11-15

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Strong Buy

Reiterates

$5.5

2024-08-13

Reason

HC Wainwright & Co.

Swayampakula Ramakanth

Price Target

$5.5

2024-08-13

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Leap Therapeutics Inc (LPTX.O) is -0.39, compared to its 5-year average forward P/E of -2.53. For a more detailed relative valuation and DCF analysis to assess Leap Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.53

Current PE

-0.39

Overvalued PE

-0.86

Undervalued PE

-4.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

44.61

Current PS

0.00

Overvalued PS

101.76

Undervalued PS

-12.53